Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 25

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 3
Chunk 25
---
.

Our growth and success also depend on our ability to attract and
retain highly qualified scientific, technical, sales, managerial and finance personnel. We experience intense competition for qualified
personnel, and the existence of non-competition agreements between prospective employees and their former employers may prevent us from
hiring those individuals or subject us to suit from their former employers. While we attempt to provide competitive compensation packages
to attract and retain key personnel, many of our competitors are likely to have greater resources and more experience than we have, making
it difficult for us to compete successfully for key personnel. If we cannot attract and retain sufficiently qualified technical employees
on acceptable terms, we may not be able to develop competitive products. Further, any failure to effectively integrate new personnel could
prevent us from successfully growing our company.

Scrutiny of sustainability
and environmental, social, and governance, or ESG, initiatives could increase our costs or otherwise adversely impact our business.

Public companies have recently faced scrutiny related to ESG practices
and disclosures from certain investors, capital providers, shareholder advocacy groups, other market participants and other stakeholder
groups. Such scrutiny may result in increased costs, enhanced compliance or disclosure obligations, or other adverse impacts on our business,
financial condition or results of operations. If our ESG practices and reporting do not meet investor or other stakeholder expectations,
we may be subject to investor or regulator engagement regarding such matters. Our failure to comply with any applicable ESG rules or regulations
could lead to penalties and adversely impact our reputation, access to capital and employee retention. Such ESG matters may
also impact our third-party contract manufacturers and other third parties on which we rely, which may augment or cause additional impacts
on our business, financial condition, or results of operations.

Risks Related to Our Industry

Healthcare reforms and related
reductions in pharmaceutical pricing, reimbursement and coverage by governmental authorities and third-party payors may adversely affect
our business.

The continuing increase in expenditures for healthcare has been
the subject of considerable government attention, particularly as public resources have been stretched by financial and economic crises
in the United States, Western Europe and elsewhere. Both private health insurance funds and government health authorities continue to
seek ways to reduce or contain healthcare costs, including by reducing or eliminating coverage for certain products and lowering reimbursement
levels. In many countries and regions, including the United States, Western Europe, Israel, Russia, certain countries in Central and Eastern
Europe and several countries in Latin America, pharmaceutical prices are subject to new government